Enliven Therapeutics signs $200M ATM equity distribution agreement with Jefferies

Enliven Therapeutics, Inc.

New Sales Agreement with Jefferies allows issuance of up to $200M in common stock at 3.0% commission rate.
Prior Cantor Fitzgerald ATM terminated; had raised $1.4M of its $75M capacity before termination.
Proceeds to fund R&D for ELVN-001, ELVN-002, other preclinical programs, and general corporate purposes.
Registration Statement (S-3) filed but not yet effective; no sales may occur until declared effective by SEC.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Enliven Therapeutics, Inc. terminated Controlled Equity Offering SM Sales Agreement (the "Prior Sales Agreement") with Cantor Fitzgerald & Co. (effective 2023-06-23).

Action: termination
Agreement: atm program
Counterparty: Cantor Fitzgerald & Co.
Effective: 2023-06-23

Exact text from the filing

On June 23, 2023, the Company delivered written notice to Cantor Fitzgerald to terminate the Prior Sales Agreement pursuant to Section 12(b) thereof, effective as of June 23, 2023.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Enliven Therapeutics, Inc. entered into Open Market Sale Agreement SM (the "Sales Agreement") with Jefferies LLC valued at up to $200.0 million (effective 2023-06-23).

Action: entry
Agreement: atm program
Counterparty: Jefferies LLC
Value: up to $200.0 million
Effective: 2023-06-23

Exact text from the filing

On June 23, 2023, Enliven Therapeutics, Inc. (the "Company") entered into an Open Market Sale Agreement SM (the "Sales Agreement") with Jefferies LLC as the Company's sales agent (the "Agent"), pursuant to which the Company may offer and sell shares (the "Shares") of its common stock, par value $0.001 per share ("Common Stock") from time to time through the Agent, in such share amounts as the Company may specify by notice to the Agent, in accordance with the terms and conditions set forth in the Sales Agreement.

View on SEC.gov

Browse all material agreements →

Enliven Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-174006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.